GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
GH Research PLCNASDAQ: GHRS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.79M, compared with -$10.73M a year earlier. Trailing-twelve-month EBITDA was -$55.86M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -23.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.79M-34.6% QoQ
- Last fiscal yearDec 2025
- -$47.46M-23.0% YoY
- LTMMar 2026
- -$55.86M-33.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -75.2% | +100.0% | +175.2 pp |
| 1 year | -23.0% | +100.0% | +123.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (47.46M) USD
- Year-over-year change
- -23.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (47.46M) | -23.0% |
| FY2024 | 2024-12-31 | (38.6M) | -9.6% |
| FY2023 | 2023-12-31 | (35.21M) | -57.1% |
| FY2022 | 2022-12-31 | (22.41M) | -144.3% |
| FY2021 | 2021-12-31 | (9.17M) | — |
EBITDA vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's LTM Mar 2026 EBITDA of -$55.86M is the 2nd highest of the 9 companies compared; the peer median is -$208.27M.
- Its year-over-year change of -33.8% is the 5th highest of 8, against a peer median of -28.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$55.86M | -33.8% | — | — | |
| LTM Mar 2026 | -$71.29M | -16.9% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Mar 2026 | -$198.91M | -147.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$323.53M | -99.1% | — | — |
| LTM Jun 2026 | -$394.35M | -3608.6% | — | — | |
| LTM Jun 2026 | -$574.94M | +24.1% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | -$208.27M | -28.2% | — | 590.7% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 335K |
| Gross Profit | 0 | 0 | 0 | 0 | (335K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M |
| Selling, General & Admin | 6.54M | 10.06M | 11.12M | 15M | 21.61M |
| Operating Expenses | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| EBITDA | (9.17M) | (22.41M) | (35.21M) | (38.6M) | (47.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.1M) | (30.55M) | (41.22M) | (50.31M) | (60.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 9 | 858K | 1.89M | 2.63M | 2.63M |
| Interest Expense | 9K | — | 723K | 717K | 463K |
| Other Income / Expenses | 5.9M | 8.1M | 5.64M | 11.35M | 12.42M |
| Income Before Tax | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| EPS (Diluted) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| Weighted Avg Shares | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Weighted Avg Shares (Diluted) | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.